NCT07947966
Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
StatusNot Yet Recruiting
PhasePhase 1
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Endpoints
Primary
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 16 weeks
Severity of TEAEs
Timeframe: Up to 16 weeks
Occurrence of TEAEs
Timeframe: Up to 27 weeks
Secondary (4)
Concentration of REGN20566 in serum
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Magnitude of ADA to REGN20566
Occurrence of ADA to REGN20566
Arms and interventions
Part AExperimental
Part BPlacebo comparator
Drugs: REGN20566, Placebo